Skip to content

4536.T

SANTEN PHARMACEUTICAL CO.,LTD.

プライム · 医薬品 · 医薬品 · JP

JPY 1,770.50
+0.97%
Ask drillr

Income statement

MetricTTM2026202520242023
Revenue
Total Revenue291.6B291.6B300.0B302.0B279.0B
Cost of Revenue—121.9B129.0B123.3B113.0B
Gross Profit—169.7B171.0B178.7B166.1B
Operating Expenses
R&D Expense—————
SG&A Expense—89.6B88.0B91.5B96.3B
General & Admin Expense—————
Selling & Marketing Expense—————
Other Expenses—4.4B3.9B15.3B38.6B
Total Operating Expenses—94.0B91.8B106.8B134.9B
Cost and Expenses243.8B243.8B253.1B263.4B282.1B
Operating Income (EBIT)47.8B47.8B46.9B38.5B(3.1B)
Non-Operating
Interest Income—1.6B4.0B1.6B1.2B
Interest Expense—2.0B2.7B2.7B1.5B
Net Interest Income—(355.0M)1.3B(1.1B)(346.0M)
Other Non-Op Income/Expense—7.0B589.0M1.5B3.5B
Non-Operating Income (excl Interest)—————
EBT (Pre-Tax Income)—47.4B47.5B29.9B(5.8B)
Income Tax Expense—9.9B11.6B3.2B9.2B
Bottom Line
Net Income37.4B37.4B36.3B26.6B(14.9B)
Earnings from Cont. Ops—————
Earnings from Discont. Ops—————
Bottom Line Net Income37.6B37.6B35.9B26.7B(15.0B)
Per Share
Basic EPS¥113¥114¥104¥73(¥39)
Diluted EPS¥113¥114¥104¥72(¥39)
Revenue Per Share¥890¥890¥861¥823¥720
Shares
Basic Shares Outstanding327.6M327.6M348.6M366.9M387.4M
Diluted Shares Outstanding—————
Profitability Metrics
EBITDA31.7B66.2B64.8B56.7B14.2B
D&A13.8B18.4B17.9B18.2B17.2B
EBIT47.8B47.8B46.9B38.5B(3.1B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026